Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | DBH | P09172 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenisonone SCHEMBL11289981 | 0.98 | KDM4E (0.62) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL4394358 | 0.83 | KDM4E (0.57) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL9768253 | 0.79 | KDM4E (0.61) | KDM4EGAADBHRECQLHDAC6 | |
| Hydrochloric Acid SCHEMBL11283638 | 0.79 | KDM4E (0.56) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL8471397 | 0.79 | KDM4E (1.00) | KDM4EGAADBHRECQLHDAC6 | |
| Hydrochloric Acid SCHEMBL11280550 | 0.78 | SLC6A3 (0.63) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL15631139 | 0.78 | HDAC6 (0.60) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL9768067 | 0.78 | KDM4E (0.54) | KDM4EGAADBHRECQLHDAC6 | |
| SCHEMBL2988488 | 0.77 | KDM4E (0.74) | KDM4EGAADBHRECQLHDAC6 | |
| Hydrochloric Acid SCHEMBL11694725 | 0.77 | KDM4E (0.49) | KDM4EGAADBHRECQLHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| CN-101203214-A | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2008-06-18 | — | — | CN | claimed |
| WO-2006108424-A9 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEV AS (DK) | 2007-08-09 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1719507-A1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | Astion Development A/S (DK) | 2006-11-08 | — | — | EP | claimed |
| WO-2006108424-A2 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | KDM4E 2292/4885GAA 2700/4885DBH 1276/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | KDM4E 2292/4885GAA 2700/4885DBH 1276/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | KDM4E 4426/4885GAA 2444/4885DBH 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.